J. Goldman & CO LP Biocryst Pharmaceuticals Inc Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $531,044 - $1.2 Million	-67,306 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $778,057 - $1.33 Million	67,306 New	67,306 $1.09 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $398,081 - $1.02 Million	-118,125 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $829,439 - $1.34 Million	-241,819 Reduced 67.18%	118,125 $406,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $683,893 - $2.02 Million	359,944 New	359,944 $1.72 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.